Since the production of the first tumor immunotherapy drug (IFN-a) and the latest immunotherapy regimes like checkpoint inhibitors (PD-L1, CTLA-4), CAR T cell therapy, tumor vaccines and oncolytic viruses, nanotherapy has become a new exemplar for clinical cancer treatment (14–16). Here, CTLA4 is linked to neoplasm.